Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (381-390 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2023
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumoursDamian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2020
Peptide Receptor Radionuclide Therapy with <sup>67</sup>Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor ModelCarleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Neuroendocrinology|April 14, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnaloguesRodney J Hicks, Dik J Kwekkeboom, Eric Krenning, et al.
Journal of Medicinal Chemistry|April 7, 2021
A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive CancerAlicia Corlett, Marc-Antoine Sani, Jessica Van Zuylekom, et al.
The Journal of Clinical Endocrinology and Metabolism|January 23, 2016
Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and ParagangliomaAidan Flynn, Trisha Dwight, Jessica Harris, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2024
A cutting-edge technology for the future of nuclear medicineAndor W J M Glaudemans, Adriaan A Lammertsma, Simon R Cherry, et al.
Journal of Medicinal Chemistry|August 21, 2009
Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearanceIvan Greguric, Stephen R Taylor, Delphine Denoyer, et al.
Endocrine-Related Cancer|May 27, 2025
Peptide receptor radionuclide therapy in malignant insulinomaDavid A Pattison, Grace Kong, Timothy Akhurst, et al.
International Journal of Radiation Biology|February 24, 2016
Strand breakage by decay of DNA-bound <sup>124</sup>I provides a basis for combined PET imaging and Auger endoradiotherapyPavel Lobachevsky, George R Clark, Patrycja D Pytel, et al.
Journal of Neuroendocrinology|October 25, 2021
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumoursClarisse Dromain, Marie-Pierre Vullierme, Rodney J Hicks, et al.
Pageof 48

Showing results (381-390 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2023
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumoursDamian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2020
Peptide Receptor Radionuclide Therapy with <sup>67</sup>Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor ModelCarleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Neuroendocrinology|April 14, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnaloguesRodney J Hicks, Dik J Kwekkeboom, Eric Krenning, et al.
Journal of Medicinal Chemistry|April 7, 2021
A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive CancerAlicia Corlett, Marc-Antoine Sani, Jessica Van Zuylekom, et al.
The Journal of Clinical Endocrinology and Metabolism|January 23, 2016
Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and ParagangliomaAidan Flynn, Trisha Dwight, Jessica Harris, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2024
A cutting-edge technology for the future of nuclear medicineAndor W J M Glaudemans, Adriaan A Lammertsma, Simon R Cherry, et al.
Journal of Medicinal Chemistry|August 21, 2009
Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearanceIvan Greguric, Stephen R Taylor, Delphine Denoyer, et al.
Endocrine-Related Cancer|May 27, 2025
Peptide receptor radionuclide therapy in malignant insulinomaDavid A Pattison, Grace Kong, Timothy Akhurst, et al.
International Journal of Radiation Biology|February 24, 2016
Strand breakage by decay of DNA-bound <sup>124</sup>I provides a basis for combined PET imaging and Auger endoradiotherapyPavel Lobachevsky, George R Clark, Patrycja D Pytel, et al.
Journal of Neuroendocrinology|October 25, 2021
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumoursClarisse Dromain, Marie-Pierre Vullierme, Rodney J Hicks, et al.
Pageof 48